Literature DB >> 18241072

A quantitative assessment of tremor and ataxia in FMR1 premutation carriers using CATSYS.

Dalila Aguilar1, Kathryn E Sigford, Kultida Soontarapornchai, Danh V Nguyen, Patrick E Adams, Jennifer M Yuhas, Flora Tassone, Paul J Hagerman, Randi J Hagerman.   

Abstract

While an established protocol exists for diagnosing individuals with the fragile X-associated tremor/ataxia syndrome (FXTAS), a quantitative measure of tremor and ataxia is needed. Using the CATSYS system to quantify movement abnormalities, we were able to record tremor, postural sway, manual (hand and finger) coordination, and reaction time in males with the FMR1 premutation, both with and without FXTAS, and compare them to controls. We evaluated 16 males diagnosed with FXTAS, 16 males with the premutation without FXTAS (non-FXTAS), and 14 age-matched controls. The CATSYS system detected, in the dominant hand, a difference in intention tremor between the FXTAS group and controls (P = 0.0008). The 30-sec postural sway tasks revealed differences between the FXTAS group and controls, both with eyes open and closed (P = 0.0004 and P = 0.0031, respectively). There was also a difference between FXTAS and non-FXTAS 30-sec postural sway performances with eyes open (P = 0.0008). The 10-sec postural sway tasks (with eyes closed) served to confirm the differences between the FXTAS group and both the controls (P = 0.0017) and non-FXTAS premutation carriers (P = 0.0016). These results demonstrate that the quantitative measures of the CATSYS system can document significant differences in intention tremor and postural sway in patients with FXTAS compared to controls. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18241072     DOI: 10.1002/ajmg.a.32211

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  17 in total

1.  Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  J Y Wang; A M Trivedi; N R Carrillo; J Yang; A Schneider; C Giulivi; P Adams; F Tassone; K Kim; S M Rivera; N Lubarr; C-Y Wu; R W Irwin; R D Brinton; J M Olichney; M A Rogawski; R J Hagerman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 2.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

Review 3.  Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials.

Authors:  Jonas Alex Morales Saute; Karina Carvalho Donis; Carmen Serrano-Munuera; David Genis; Luís Torres Ramirez; Pilar Mazzetti; Luis Velázquez Pérez; Pilar Latorre; Jorge Sequeiros; Antoni Matilla-Dueñas; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

4.  Prepulse inhibition in patients with fragile X-associated tremor ataxia syndrome.

Authors:  Andrea Schneider; Elizabeth Ballinger; Alyssa Chavez; Flora Tassone; Randi J Hagerman; David Hessl
Journal:  Neurobiol Aging       Date:  2010-10-20       Impact factor: 4.673

5.  Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine.

Authors:  Melina C Ortigas; James A Bourgeois; Andrea Schneider; John Olichney; Danh V Nguyen; Jennifer B Cogswell; Deborah A Hall; Randi J Hagerman
Journal:  J Clin Psychopharmacol       Date:  2010-10       Impact factor: 3.153

6.  Clinical involvement in daughters of men with fragile X-associated tremor ataxia syndrome.

Authors:  W Chonchaiya; D V Nguyen; J Au; L Campos; E M Berry-Kravis; K Lohse; Y Mu; A Utari; C Hervey; L Wang; P Sorensen; K Cook; L Gane; F Tassone; R J Hagerman
Journal:  Clin Genet       Date:  2010-04-14       Impact factor: 4.438

7.  Characterization and Early Detection of Balance Deficits in Fragile X Premutation Carriers With and Without Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS).

Authors:  Joan A O'Keefe; Erin Robertson-Dick; Emily J Dunn; Yan Li; Youping Deng; Amber N Fiutko; Elizabeth Berry-Kravis; Deborah A Hall
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

8.  Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Andreea L Seritan; Danh V Nguyen; Yi Mu; Flora Tassone; James A Bourgeois; Andrea Schneider; Jennifer B Cogswell; Kylee R Cook; Maureen A Leehey; Jim Grigsby; John M Olichney; Patrick E Adams; Wendi Legg; Lin Zhang; Paul J Hagerman; Randi J Hagerman
Journal:  J Clin Psychiatry       Date:  2014-03       Impact factor: 4.384

Review 9.  Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) Motor Dysfunction Modeled in Mice.

Authors:  Molly Foote; Gloria Arque; Robert F Berman; Mónica Santos
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

10.  A Quantitative Assessment of Tremor and Ataxia in Female FMR1 Premutation Carriers Using CATSYS.

Authors:  Vivien Narcisa; Dalila Aguilar; Danh V Nguyen; Luis Campos; Jeffrey Brodovsky; Shana White; Patrick Adams; Flora Tassone; Paul J Hagerman; Randi J Hagerman
Journal:  Curr Gerontol Geriatr Res       Date:  2011-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.